LONDON — GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a promising chronic cough drug to its pipeline.
The all-cash deal values Bellus, based in Laval, Canada, at $14.75 a share, roughly double Monday’s closing stock price.
With the acquisition, GSK will get the experimental drug camlipixant, which is in a Phase 3 trial for refractory chronic cough. A readout from the study is expected in the second half of 2024, Bellus has said previously. GSK said it anticipates the medicine could receive regulatory approval in 2026.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
